SCHEMBL4923725

SCHEMBL4923725

Cc1onc(-c2ccccc2)c1C(=O)c1sc(S(C)(=O)=O)c2c1CC(C)(C)CC2=O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
LRRK2 Q5S007 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 1/20 0.40
HPGD P15428 2/20 0.40
BRD4 O60885 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PTBP1 P26599 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919003 0.80 LRRK2 (0.46) ALDH1A1LRRK2KMT2AMEN1GAA
SCHEMBL4927639 0.76 LRRK2 (0.44) ALDH1A1LRRK2GAALMNASMN1; SMN2
SCHEMBL4927720 0.75 LRRK2 (0.48) ALDH1A1LRRK2KMT2AGAALMNA
SCHEMBL4923074 0.74 LRRK2 (0.46) ALDH1A1LRRK2KMT2AGAALMNA
SCHEMBL4925973 0.74 LRRK2 (0.46) ALDH1A1LRRK2KMT2AMEN1LMNA
SCHEMBL4923028 0.74 ALDH1A1 (0.50) ALDH1A1LRRK2KMT2AMEN1GAA
SCHEMBL4921837 0.73 LRRK2 (0.43) ALDH1A1LRRK2LMNASMN1; SMN2HTT
SCHEMBL4922740 0.73 LRRK2 (0.41) ALDH1A1LRRK2KMT2AMEN1LMNA
SCHEMBL4921995 0.73 LRRK2 (0.54) ALDH1A1LRRK2GAASMN1; SMN2HPGD
SCHEMBL4930298 0.73 LRRK2 (0.52) ALDH1A1LRRK2KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
EP-1765814-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006003096-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists GLP1R, GIPR, GCGR ALDH1A1 2002/4885LRRK2 327/4885KMT2A 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.